{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:05:38Z","timestamp":1788174338269,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["APP1142008"],"award-info":[{"award-number":["APP1142008"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Research Australia","doi-asserted-by":"publisher","award":["G173565"],"award-info":[{"award-number":["G173565"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sydney Research Excellence Initiative 2020","award":["G201115"],"award-info":[{"award-number":["G201115"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40478-019-0786-3","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T10:05:43Z","timestamp":1567505143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination"],"prefix":"10.1186","volume":"7","author":[{"name":"the Australasian and New Zealand MOG Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Tea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Merheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona X. Z.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Pilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"Tantsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eppie M.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P. D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare L.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"Lunemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-2276","authenticated-orcid":false,"given":"Fabienne","family":"Brilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"786_CR1","doi-asserted-by":"publisher","unstructured":"Amatoury M, Merheb V, Langer J, Wang XM, Dale RC, Brilot F (2013) High-throughput flow cytometry cell-based assay to detect antibodies to N-methyl-D-aspartate receptor or dopamine-2 receptor in human serum. J Vis Exp:e50935. https:\/\/doi.org\/10.3791\/50935","DOI":"10.3791\/50935"},{"key":"786_CR2","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","volume":"2","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, O\u2019Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Budingen HC, Stuve O, Yeaman MR, Smith TJ et al (2015) B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e104. https:\/\/doi.org\/10.1212\/NXI.0000000000000104","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"786_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0165-5728(99)00010-7","volume":"97","author":"U Brehm","year":"1999","unstructured":"Brehm U, Piddlesden SJ, Gardinier MV, Linington C (1999) Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol 97:9\u201315","journal-title":"J Neuroimmunol"},{"key":"786_CR4","doi-asserted-by":"publisher","first-page":"9446","DOI":"10.1073\/pnas.1133443100","volume":"100","author":"C Breithaupt","year":"2003","unstructured":"Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, Jacob U (2003) Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A 100:9446\u20139451. https:\/\/doi.org\/10.1073\/pnas.1133443100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"786_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","volume":"66","author":"F Brilot","year":"2009","unstructured":"Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, Busch V, Zhou D, Cepok S, Hemmer B (2009) Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66:833\u2013842. https:\/\/doi.org\/10.1002\/ana.21916","journal-title":"Ann Neurol"},{"key":"786_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"key":"786_CR7","doi-asserted-by":"publisher","first-page":"11059","DOI":"10.1073\/pnas.1833158100","volume":"100","author":"CS Clements","year":"2003","unstructured":"Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG, Bernard CC, Rossjohn J (2003) The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci U S A 100:11059\u201311064. https:\/\/doi.org\/10.1073\/pnas.1833158100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"786_CR8","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90:e1858\u2013e1869. https:\/\/doi.org\/10.1212\/WNL.0000000000005560","journal-title":"Neurology"},{"key":"786_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","volume":"266","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sepulveda M, d\u2019Indy H, Armangue T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D et al (2019) Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. J Neurol 266:806\u2013815. https:\/\/doi.org\/10.1007\/s00415-018-9160-9","journal-title":"J Neurol"},{"key":"786_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sepulveda M, Rollot F, Armangue T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D et al (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 16:134. https:\/\/doi.org\/10.1186\/s12974-019-1525-1","journal-title":"J Neuroinflammation"},{"issue":"3","key":"786_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0000000000000681","volume":"32","author":"Alvaro Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Vukusic S, Marignier R (2019) Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Curr Opin Neurol. https:\/\/doi.org\/10.1097\/WCO.0000000000000681","journal-title":"Current Opinion in Neurology"},{"key":"786_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","volume":"83","author":"RC Dale","year":"2014","unstructured":"Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR et al (2014) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 83:142\u2013150. https:\/\/doi.org\/10.1212\/WNL.0000000000000570","journal-title":"Neurology"},{"key":"786_CR13","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1212\/NXI.0000000000000012","volume":"1","author":"RC Dale","year":"2014","unstructured":"Dale RC, Tantsis EM, Merheb V, Kumaran RY, Sinmaz N, Pathmanandavel K, Ramanathan S, Booth DR, Wienholt LA, Prelog K et al (2014) Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 1:e12. https:\/\/doi.org\/10.1212\/NXI.0000000000000012","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"786_CR14","doi-asserted-by":"publisher","first-page":"17206","DOI":"10.1074\/jbc.M111.304246","volume":"287","author":"KL de Graaf","year":"2012","unstructured":"de Graaf KL, Albert M, Weissert R (2012) Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity. J Biol Chem 287:17206\u201317213. https:\/\/doi.org\/10.1074\/jbc.M111.304246","journal-title":"J Biol Chem"},{"key":"786_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3389\/fimmu.2018.02753","volume":"9","author":"F Di Pauli","year":"2018","unstructured":"Di Pauli F, Berger T (2018) Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders? Front Immunol 9:2753. https:\/\/doi.org\/10.3389\/fimmu.2018.02753","journal-title":"Front Immunol"},{"key":"786_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1084\/jem.190.11.1689","volume":"190","author":"L Fossati-Jimack","year":"1999","unstructured":"Fossati-Jimack L, Reininger L, Chicheportiche Y, Clynes R, Ravetch JV, Honjo T, Izui S (1999) High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. J Exp Med 190:1689\u20131696","journal-title":"J Exp Med"},{"key":"786_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/jnr.490330123","volume":"33","author":"MV Gardinier","year":"1992","unstructured":"Gardinier MV, Amiguet P, Linington C, Matthieu JM (1992) Myelin\/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res 33:177\u2013187. https:\/\/doi.org\/10.1002\/jnr.490330123","journal-title":"J Neurosci Res"},{"key":"786_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","volume":"21","author":"Y Hacohen","year":"2019","unstructured":"Hacohen Y, Banwell B (2019) Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol 21:2. https:\/\/doi.org\/10.1007\/s11940-019-0541-x","journal-title":"Curr Treat Options Neurol"},{"key":"786_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75:478\u2013487. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4601","journal-title":"JAMA Neurol"},{"key":"786_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0037-1604404","volume":"49","author":"EM Hennes","year":"2018","unstructured":"Hennes EM, Baumann M, Lechner C, Rostasy K (2018) MOG spectrum disorders and role of MOG-antibodies in clinical practice. Neuropediatrics 49:3\u201311. https:\/\/doi.org\/10.1055\/s-0037-1604404","journal-title":"Neuropediatrics"},{"key":"786_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","volume":"291","author":"MG Huijbers","year":"2016","unstructured":"Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-Garcia R, Diaz-Manera J, Kuks JB, Klooster R et al (2016) Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J Neuroimmunol 291:82\u201388. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.12.016","journal-title":"J Neuroimmunol"},{"key":"786_CR22","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.4049\/jimmunol.152.9.4489","volume":"152","author":"BA Jacobson","year":"1994","unstructured":"Jacobson BA, Sharon J, Shan H, Shlomchik M, Weigert MG, Marshakrothstein A (1994) An isotype switched and somatically mutated rheumatoid-factor clone Isolated from a Mrl-Lpr\/Lpr mouse exhibits limited intraclonal affinity maturation. J Immunol 152:4489\u20134499","journal-title":"J Immunol"},{"key":"786_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflammation"},{"key":"786_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13:280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0","journal-title":"J Neuroinflammation"},{"key":"786_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13:279. https:\/\/doi.org\/10.1186\/s12974-016-0717-1","journal-title":"J Neuroinflammation"},{"key":"786_CR26","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, Tackley G, Hamid S, Sheard A, Reynolds G et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140:3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"786_CR27","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","volume":"2","author":"SM Kim","year":"2015","unstructured":"Kim SM, Woodhall MR, Kim JS, Kim SJ, Park KS, Vincent A, Lee KW, Waters P (2015) Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2:e163. https:\/\/doi.org\/10.1212\/NXI.0000000000000163","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"786_CR28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273\u20131277. https:\/\/doi.org\/10.1212\/WNL.0b013e31826aac4e","journal-title":"Neurology"},{"key":"786_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/acn3.418","volume":"4","author":"MC Kowarik","year":"2017","unstructured":"Kowarik MC, Astling D, Gasperi C, Wemlinger S, Schumann H, Dzieciatkowska M, Ritchie AM, Hemmer B, Owens GP, Bennett JL (2017) CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 4:369\u2013380. https:\/\/doi.org\/10.1002\/acn3.418","journal-title":"Ann Clin Transl Neurol"},{"key":"786_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","volume":"19","author":"LB Krupp","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D et al (2013) International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261\u20131267. https:\/\/doi.org\/10.1177\/1352458513484547","journal-title":"Mult Scler"},{"key":"786_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","volume":"3","author":"K Kurosawa","year":"2015","unstructured":"Kurosawa K, Misu T, Takai Y, Sato DK, Takahashi T, Abe Y, Iwanari H, Ogawa R, Nakashima I, Fujihara K et al (2015) Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. Acta Neuropathol Commun 3:82. https:\/\/doi.org\/10.1186\/s40478-015-0259-2","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"786_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/WCO.0000000000000685","volume":"32","author":"Hans Lassmann","year":"2019","unstructured":"Lassmann H (2019) The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders. Curr Opin Neurol. https:\/\/doi.org\/10.1097\/WCO.0000000000000685","journal-title":"Current Opinion in Neurology"},{"key":"786_CR33","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131:1940\u20131952. https:\/\/doi.org\/10.1093\/brain\/awn092","journal-title":"Brain"},{"key":"786_CR34","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","volume":"191","author":"MC Mayer","year":"2013","unstructured":"Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostasy K, Berger T, Dale RC, Brilot F, Olsson T, Jenne D et al (2013) Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 191:3594\u20133604. https:\/\/doi.org\/10.4049\/jimmunol.1301296","journal-title":"J Immunol"},{"key":"786_CR35","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","volume":"183","author":"KA McLaughlin","year":"2009","unstructured":"McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, Kuhle J, Kappos L, Rostasy K, Pohl D et al (2009) Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 183:4067\u20134076. https:\/\/doi.org\/10.4049\/jimmunol.0801888","journal-title":"J Immunol"},{"key":"786_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1742-2094-8-161","volume":"8","author":"T Menge","year":"2011","unstructured":"Menge T, Lalive PH, von Budingen HC, Genain CP (2011) Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 8:161. https:\/\/doi.org\/10.1186\/1742-2094-8-161","journal-title":"J Neuroinflammation"},{"key":"786_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1021\/bc050340f","volume":"17","author":"B Metz","year":"2006","unstructured":"Metz B, Kersten GF, Baart GJ, de Jong A, Meiring H, ten Hove J, van Steenbergen MJ, Hennink WE, Crommelin DJ, Jiskoot W (2006) Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem 17:815\u2013822. https:\/\/doi.org\/10.1021\/bc050340f","journal-title":"Bioconjug Chem"},{"key":"786_CR38","doi-asserted-by":"publisher","first-page":"1365175","DOI":"10.1155\/2018\/1365175","volume":"2018","author":"SH Mohseni","year":"2018","unstructured":"Mohseni SH, Skejoe HPB, Wuerfel J, Paul F, Reindl M, Jarius S, Asgari N (2018) Leptomeningeal and intraparenchymal blood barrier disruption in a MOG-IgG-positive patient. Case Rep Neurol Med 2018:1365175. https:\/\/doi.org\/10.1155\/2018\/1365175","journal-title":"Case Rep Neurol Med"},{"key":"786_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O\u2019Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH, Cherry SV, Bar-Or A, Banwell B et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211\u2013217. https:\/\/doi.org\/10.1038\/nm1488","journal-title":"Nat Med"},{"key":"786_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","volume":"14","author":"P Peschl","year":"2017","unstructured":"Peschl P, Schanda K, Zeka B, Given K, Bohm D, Ruprecht K, Saiz A, Lutterotti A, Rostasy K, Hoftberger R et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation 14:208. https:\/\/doi.org\/10.1186\/s12974-017-0984-5","journal-title":"J Neuroinflammation"},{"key":"786_CR41","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.20090299","volume":"206","author":"B Pollinger","year":"2009","unstructured":"Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, Dunn R, Domingues HS, Holz A, Kurschus FC, Wekerle H (2009) Spontaneous relapsing-remitting EAE in the SJL\/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 206:1303\u20131316. https:\/\/doi.org\/10.1084\/jem.20090299","journal-title":"J Exp Med"},{"key":"786_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"77","author":"AK Probstel","year":"2011","unstructured":"Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, Villalobos A, Breithaupt C, Weissert R, Jacob U et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580\u2013588. https:\/\/doi.org\/10.1212\/WNL.0b013e318228c0b1","journal-title":"Neurology"},{"key":"786_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","volume":"12","author":"AK Probstel","year":"2015","unstructured":"Probstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T (2015) Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation 12:46. https:\/\/doi.org\/10.1186\/s12974-015-0256-1","journal-title":"J Neuroinflammation"},{"key":"786_CR44","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1212\/WNL.0000000000001066","volume":"83","author":"FJ Quintana","year":"2014","unstructured":"Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, Fetco D, Hussain M, O\u2019Mahony J, Magalhaes S et al (2014) Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology 83:2219\u20132226. https:\/\/doi.org\/10.1212\/WNL.0000000000001066","journal-title":"Neurology"},{"key":"786_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15:307\u2013324. https:\/\/doi.org\/10.1016\/j.autrev.2015.12.004","journal-title":"Autoimmun Rev"},{"key":"786_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/ene.13932","volume":"26","author":"S Ramanathan","year":"2019","unstructured":"Ramanathan S, Fraser C, Curnow SR, Ghaly M, Leventer RJ, Lechner-Scott J, Henderson A, Reddel S, Dale RC, Brilot F (2019) Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. Eur J Neurol 26:1137\u2013e1175. https:\/\/doi.org\/10.1111\/ene.13932","journal-title":"Eur J Neurol"},{"key":"786_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89:127\u2013137. https:\/\/doi.org\/10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"786_CR48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dmcn.14032","volume":"61","author":"S Ramanathan","year":"2019","unstructured":"Ramanathan S, O\u2019Grady GL, Malone S, Spooner CG, Brown DA, Gill D, Brilot F, Dale RC (2019) Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. Dev Med Child Neurol 61:610\u2013614. https:\/\/doi.org\/10.1111\/dmcn.14032","journal-title":"Dev Med Child Neurol"},{"key":"786_CR49","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, Merheb V, Kumaran RY, Pathmanandavel K, Sinmaz N et al (2014) Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1:e40. https:\/\/doi.org\/10.1212\/NXI.0000000000000040","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"786_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/135245859800400302","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H (1998) Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 4:99\u2013107. https:\/\/doi.org\/10.1177\/135245859800400302","journal-title":"Mult Scler"},{"key":"786_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/135245859800400304","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H, Ungefehr S, Jacobi C (1998) The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 4:111\u2013117. https:\/\/doi.org\/10.1177\/135245859800400304","journal-title":"Mult Scler"},{"key":"786_CR52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15:89\u2013102. https:\/\/doi.org\/10.1038\/s41582-018-0112-x","journal-title":"Nat Rev Neurol"},{"key":"786_CR53","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474\u2013481. https:\/\/doi.org\/10.1212\/WNL.0000000000000101","journal-title":"Neurology"},{"key":"786_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1369\/0022155416673995","volume":"65","author":"CR Scalia","year":"2017","unstructured":"Scalia CR, Boi G, Bolognesi MM, Riva L, Manzoni M, DeSmedt L, Bosisio FM, Ronchi S, Leone BE, Cattoretti G (2017) Antigen masking during fixation and embedding, dissected. J Histochem Cytochem 65:5\u201320. https:\/\/doi.org\/10.1369\/0022155416673995","journal-title":"J Histochem Cytochem"},{"key":"786_CR55","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","volume":"263","author":"M Sepulveda","year":"2016","unstructured":"Sepulveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Tellez N, Midaglia L, Arino H, Peschl P et al (2016) Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 263:1349\u20131360. https:\/\/doi.org\/10.1007\/s00415-016-8147-7","journal-title":"J Neurol"},{"key":"786_CR56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12974-016-0678-4","volume":"13","author":"N Sinmaz","year":"2016","unstructured":"Sinmaz N, Nguyen T, Tea F, Dale RC, Brilot F (2016) Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. J Neuroinflammation 13:219. https:\/\/doi.org\/10.1186\/s12974-016-0678-4","journal-title":"J Neuroinflammation"},{"key":"786_CR57","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, Metz I, Blaschek A, Dick A, Bruck W et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3:e257. https:\/\/doi.org\/10.1212\/NXI.0000000000000257","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"786_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltran E, Macrini C, Hoftberger R, Schuh E, Thaler FS, Gerdes LA, Laurent S, Gerhards R et al (2018) Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 84:315\u2013328. https:\/\/doi.org\/10.1002\/ana.25291","journal-title":"Ann Neurol"},{"key":"786_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ymeth.2015.05.006","volume":"89","author":"S Srinivasa","year":"2015","unstructured":"Srinivasa S, Ding X, Kast J (2015) Formaldehyde cross-linking and structural proteomics: bridging the gap. Methods 89:91\u201398. https:\/\/doi.org\/10.1016\/j.ymeth.2015.05.006","journal-title":"Methods"},{"key":"786_CR60","doi-asserted-by":"publisher","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","volume":"2","author":"P Stathopoulos","year":"2017","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O\u2019Connor KC (2017) Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. Jci Insight 2:e94263. https:\/\/doi.org\/10.1172\/jci.insight.94263","journal-title":"Jci Insight"},{"key":"786_CR61","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jms.1415","volume":"43","author":"BW Sutherland","year":"2008","unstructured":"Sutherland BW, Toews J, Kast J (2008) Utility of formaldehyde cross-linking and mass spectrometry in the study of protein-protein interactions. J Mass Spectrom 43:699\u2013715. https:\/\/doi.org\/10.1002\/jms.1415","journal-title":"J Mass Spectrom"},{"key":"786_CR62","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"786_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.aca.2010.07.040","volume":"676","author":"J Toews","year":"2010","unstructured":"Toews J, Rogalski JC, Kast J (2010) Accessibility governs the relative reactivity of basic residues in formaldehyde-induced protein modifications. Anal Chim Acta 676:60\u201367. https:\/\/doi.org\/10.1016\/j.aca.2010.07.040","journal-title":"Anal Chim Acta"},{"key":"786_CR64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12974-016-0642-3","volume":"13","author":"F Tuller","year":"2016","unstructured":"Tuller F, Holzer H, Schanda K, Aboulenein-Djamshidian F, Hoftberger R, Khalil M, Seifert-Held T, Leutmezer F, Berger T, Reindl M (2016) Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. J Neuroinflammation 13:176. https:\/\/doi.org\/10.1186\/s12974-016-0642-3","journal-title":"J Neuroinflammation"},{"key":"786_CR65","first-page":"347","volume":"48","author":"VK Tuohy","year":"2000","unstructured":"Tuohy VK, Kinkel RP (2000) Epitope spreading: a mechanism for progression of autoimmune disease. Arch Immunol Ther Exp 48:347\u2013351","journal-title":"Arch Immunol Ther Exp"},{"key":"786_CR66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jim.2006.09.009","volume":"317","author":"K Vani","year":"2006","unstructured":"Vani K, Bogen SA, Sompuram SR (2006) A high throughput combinatorial library technique for identifying formalin-sensitive epitopes. J Immunol Methods 317:80\u201389. https:\/\/doi.org\/10.1016\/j.jim.2006.09.009","journal-title":"J Immunol Methods"},{"key":"786_CR67","doi-asserted-by":"publisher","first-page":"8207","DOI":"10.1073\/pnas.122092499","volume":"99","author":"HC von Budingen","year":"2002","unstructured":"von Budingen HC, Hauser SL, Fuhrmann A, Nabavi CB, Lee JI, Genain CP (2002) Molecular characterization of antibody specificities against myelin\/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci U S A 99:8207\u20138212. https:\/\/doi.org\/10.1073\/pnas.122092499","journal-title":"Proc Natl Acad Sci U S A"},{"key":"786_CR68","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/eji.200425050","volume":"34","author":"HC von Budingen","year":"2004","unstructured":"von Budingen HC, Hauser SL, Ouallet JC, Tanuma N, Menge T, Genain CP (2004) Frontline: epitope recognition on the myelin\/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol 34:2072\u20132083. https:\/\/doi.org\/10.1002\/eji.200425050","journal-title":"Eur J Immunol"},{"key":"786_CR69","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","volume":"2","author":"P Waters","year":"2015","unstructured":"Waters P, Woodhall M, O\u2019Connor KC, Reindl M, Lang B, Sato DK, Jurynczyk M, Tackley G, Rocha J, Takahashi T et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2:e89. https:\/\/doi.org\/10.1212\/NXI.0000000000000089","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"786_CR70","doi-asserted-by":"publisher","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","volume":"92","author":"PJ Waters","year":"2019","unstructured":"Waters PJ, Komorowski L, Woodhall M, Lederer S, Majed M, Fryer J, Mills J, Flanagan EP, Irani SR, Kunchok AC et al (2019) A multicenter comparison of MOG-IgG cell-based assays. Neurology 92:e1250\u2013e1255. https:\/\/doi.org\/10.1212\/WNL.0000000000007096","journal-title":"Neurology"},{"key":"786_CR71","doi-asserted-by":"publisher","first-page":"175628641876208","DOI":"10.1177\/1756286418762083","volume":"11","author":"MS Weber","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Bruck W (2018) Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord 11:1756286418762083. https:\/\/doi.org\/10.1177\/1756286418762083","journal-title":"Ther Adv Neurol Disord"},{"key":"786_CR72","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/Wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/Wnl.0000000000001729","journal-title":"Neurology"},{"key":"786_CR73","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/ene.13602","volume":"25","author":"YYM Wong","year":"2018","unstructured":"Wong YYM, Hacohen Y, Armangue T, Wassmer E, Verhelst H, Hemingway C, van Pelt ED, Catsman-Berrevoets CE, Hintzen RQ, Deiva K et al (2018) Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol 25:782\u2013786. https:\/\/doi.org\/10.1111\/ene.13602","journal-title":"Eur J Neurol"},{"key":"786_CR74","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/WNL.0000000000007077","volume":"92","author":"EA Yeh","year":"2019","unstructured":"Yeh EA, Nakashima I (2019) Live-cell based assays are the gold standard for anti-MOG-Ab testing. Neurology 92:501\u2013502. https:\/\/doi.org\/10.1212\/WNL.0000000000007077","journal-title":"Neurology"},{"key":"786_CR75","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ (2015) Does MOGIg-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol 2:e62. https:\/\/doi.org\/10.1212\/NXI.0000000000000062","journal-title":"Neurol Neuroimmunol"},{"key":"786_CR76","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1109\/TCBB.2011.49","volume":"8","author":"L Zhao","year":"2011","unstructured":"Zhao L, Wong L, Li J (2011) Antibody-specified B-cell epitope prediction in line with the principle of context-awareness. IEEE\/ACM Trans Comput Biol Bioinform 8:1483\u20131494. https:\/\/doi.org\/10.1109\/TCBB.2011.49","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-019-0786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40478-019-0786-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-019-0786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T16:01:39Z","timestamp":1695139299000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-019-0786-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["786"],"URL":"https:\/\/doi.org\/10.1186\/s40478-019-0786-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FT, JAL, VM, FZXL, AZ, DP, SV, APDH, MHB, EL, AF, CLF, DAB, JDL have no conflict of interest. SR and EMY report fellowship research funding from the National Health and Medical Research Council of Australia. SWR has received grants and personal fees from Genzyme Sanofi, personal fees and departmental support from the Government of Australia, Baxter, Biogen, CSL, and Merck; and departmental support from Novartis, outside the subject of the submitted work. SB has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Scherring, Biogen-Idec, Merck-Serono, Novartis, and Sanofi-Genzyme, has received speakers honoraria from Biogen Idec and Genzyme, is an investigator in clinical trials sponsored by Biogen Idec, Novartis and Genzyme, and was the recipient of an unencumbered research grant from Biogen-Idec. JL-S has accepted travel compensation from Novartis, Biogen, and Merck Serono. Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Bayer Health Care, Biogen, Genzyme Sanofi, Merck, Novartis and TEVA. AVDW has received travel support from Merck Serono, Novartis, Biogen, Roche, and Sanofi. She has served on scientific and commercial advisory boards for Merck, Novartis, Sanofi, and Roche, and has received unencumbered research grants from Novartis, Biogen, Merck and Roche. MM has served on scientific and commercial advisory boards for Merck Serono. RCD and FB have received research funding from The Trish Multiple Sclerosis Research Foundation, Multiple Sclerosis Research Australia, the Petre Foundation, and the National Health Medical Research Council (Australia). They have received honoraria from Biogen Idec and Merck Serono as invited speakers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}